Company: NIVFW
Filing Date: 2025-05-20
Form Type: F-1/A
Source: 0001213900-25-045737
Chunk: 166

Company: NewGenIvf Group Ltd
Filing Date: 2025-05-20
Form: F-1/A
Chunk 166
---
 Series A Warrant automatically increased to 796,118 (on a post Reverse Stock Splits basis). The Fourth Tranche Note is included as Exhibit 4.1 in the Form 6-K filed on April 3, 2025, which is incorporated herein by reference. Between November 7, 2024 and the date of this prospectus, the Company received gross proceeds of $6,450,000 and issued an aggregate of 476,166 Class A Ordinary Shares (on a post Reverse Stock Splits basis) to the Buyers. II-3 The Company may receive up to approximately $33,891,289 in additional net proceeds from the 2024 Debt Financing if (i) $6,975,000 in net proceeds are received if all remaining Additional Notes in the aggregate principal amount of $7,500,000 (together with the Fourth Tranche Note,the “Remaining Additional Notes”) issuable pursuant to the Securities Purchase Agreement are sold and (ii) the Series A Warrants are increased by 10,157,580 assuming that (A) all Remaining Additional Notes are sold and (B) an Additional Share Price is equal to $1.3513 and (iii) all of the Warrants are exercised in full, based on the following assumptions (x) approximately $23,909,021 in net proceeds are received from the exercise of the Series A Warrants, assuming that the Series A Warrants are exercised in full at an exercise price of $1.8258 and the number of Ordinary Shares issuable upon exercise of the Series A Warrants equals 13,095,093, (y) approximately $1,485 in net proceeds are received from the exercise of the Series B Warrants, assuming that the Series B Warrants are exercised in full at an exercise price of $0.020 per share, and (z) approximately $3,005,784 in net proceeds are received from the exercise of the Exchange Warrants, assuming that the Exchange Warrants are exercised in full at an exercise price of $1.8258. The foregoing is subject to adjustment as set forth in the respective Notes and Warrants, as applicable. White Lion Equity Line of Credit On November 21, 2024, the Company entered into a Common Shares Purchase Agreement (the “White Lion Purchase Agreement”) with White Lion Capital, LLC (“White Lion”) and a related Registration Rights Agreement (the “RRA”). Pursuant to the White Lion Purchase Agreement, the Company has the right, but